Technical Analysis for MLLCF - Molecular Partners Ag

Grade Last Price % Change Price Change
grade A 23.8 0.21% 0.0500
MLLCF closed up 0.21 percent on Wednesday, December 2, 2020, on 25 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical MLLCF trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.21%
Narrow Range Bar Range Contraction 0.21%
Inside Day Range Contraction 0.21%
20 DMA Support Bullish 1.71%
1,2,3 Pullback Bullish Bullish Swing Setup 1.71%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.71%
Outside Day Range Expansion 1.71%
1,2,3 Pullback Bullish Bullish Swing Setup -1.10%
Older End-of-Day Signals for MLLCF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Biopharmaceutical Drugs Cancer Immunotherapy Tumor Multiple Myeloma Pharmaceutical Companies Diabetic Macular Edema Wet Age Related Macular Degeneration Amgen

Is MLLCF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.0
52 Week Low 16.0
Average Volume 13,975
200-Day Moving Average 0.0000
50-Day Moving Average 20.1553
20-Day Moving Average 23.2064
10-Day Moving Average 23.3944
Average True Range 0.9670
ADX 29.55
+DI 31.1119
-DI 17.7449
Chandelier Exit (Long, 3 ATRs ) 21.8090
Chandelier Exit (Short, 3 ATRs ) 23.9010
Upper Bollinger Band 24.6890
Lower Bollinger Band 21.7238
Percent B (%b) 0.7
BandWidth 12.7775
MACD Line 0.9617
MACD Signal Line 1.0566
MACD Histogram -0.0949
Fundamentals Value
Market Cap 519.07 Million
Num Shares 21.8 Million
EPS
Price-to-Sales 31.08
Price-to-Book 14.52
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.8350
Resistance 3 (R3) 24.7833 24.3867 24.6625
Resistance 2 (R2) 24.3867 24.1231 24.4125 24.6050
Resistance 1 (R1) 24.0933 23.9602 24.2400 24.1450 24.5475
Pivot Point 23.6967 23.6967 23.7700 23.7225 23.6967
Support 1 (S1) 23.4033 23.4331 23.5500 23.4550 23.0525
Support 2 (S2) 23.0067 23.2702 23.0325 22.9950
Support 3 (S3) 22.7133 23.0067 22.9375
Support 4 (S4) 22.7650